N. prodotti: 0
Totale ordine: € 0,00
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6
Online ISSN 1827-1898
Yilmaz T., Akman M., Tutluoglu B.*, Afrasyaop L.**, Goylusun B., Celik N.
From the PTT Hospital, Chest Diseases Department * Istanbul University Lung Diseases and Tuberculosis Institute, Istanbul, Turkey
** PTT Hospital, Biochemistry Department, Istanbul, Turkey
Background. Thrombomodulin (TM) is a glycoprotein and besides its anticoagulant property it is accepted as an onco developmental antigen. Considering these properties we hypothesised that active TMB might have a role in cancer cell behaviour.
Methods. We measured serum TMB levels by the enzyme immunoassay method in 40 patients with lung cancer and 20 healthy subjects.
Results. TMB levels were found as 54.6±11.5 in controls and 60.9±31.2 ng/ml in lung cancer patients TM levels were 59.4±24.2 ng/ml in 24 epidermoid carcinoma patients, 65±50.2 ng/ml in 10 small cell carcinoma patients and 60±18.4 ng/ml in 6 adenocarcinoma patients. Patients with stage 4 and distant metastasis had a value of 65±33.9 ng/ml. No significant differences were found between healthy subjects and cancer patients. Also the differences between 3 groups of patients were insignificant.
Conclusions. It was concluded that serum TMB levels could not be accepted as a tumour marker in lung cancer patients.